Order Article Reprints

Hachuła M, Kosowski M, Basiak M, Okopień B. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study. Pharmaceuticals. 2023; 16(9):1190. https://doi.org/10.3390/ph16091190

Hachuła, Marcin, Michał Kosowski, Marcin Basiak, and Bogusław Okopień. 2023. "Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study" Pharmaceuticals 16, no. 9: 1190. https://doi.org/10.3390/ph16091190

Hachuła, M., Kosowski, M., Basiak, M., & Okopień, B. (2023). Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study. Pharmaceuticals, 16(9), 1190. https://doi.org/10.3390/ph16091190